Serum prolidase enzyme activity and oxidative status in patients with fibromyalgia

Redox Report

Volumn 19, Issue 4, 2014, Pages 148-153

  Bozkurt, Mehtap ^a   Caglayan, Mehmet ^a   Oktayoglu, Pelin ^a   Em, Serda ^a   Batmaz, Ibrahim ^a   Sariyildiz, Mustafa Akif ^a   Nas, Kemal ^a   Ucar, Demet ^a   Yüksel, Hatice ^a   Sarac, Aysegul Jale ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Fibromyalgia; Oxidative status; Prolidase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROLINE DIPEPTIDASE; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; DIPEPTIDASE; PON1 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DYSTHYMIA; ENZYME ACTIVITY; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MUSCLE FATIGUE; OXIDATIVE STRESS; PRIORITY JOURNAL; VISUAL ANALOG SCALE; BLOOD; ENZYMOLOGY; MALE; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY; YOUNG ADULT;

ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; DIPEPTIDASES; FEMALE; FIBROMYALGIA; HUMANS; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS; YOUNG ADULT;

EID: 84901315974     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000213Y.0000000079     Document Type: Article

References (45)

1. Ozgocmen S, Ozyurt H, Sogut S, Akyol O. Current concepts in the pathophysiology of fibromyalgia: the potential role of oxi-dative stress and nitric oxide. Rheumatol Int 2006;26(7):585-597.
2. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005;75:6-21.
3. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010;39(6):448-453.
4. Gronemann ST, Ribel-Madsen S, Bartels EM, Danneskiold-Samsoe B, Bliddal H. Collagen and muscle pathology in fibro-myalgia patients. Rheumatology (Oxford) 2004;43(1):27-31.
5. Sprott H, Muller A, Heine H. Collagen crosslinks in fibromyal-gia. Arthritis Rheum 1997;40(8):1450-1454.
6. Surazynski A, Miltyk W, Palka J, Phang JM. Prolidase-depen-dent regulation of collagen biosynthesis. Amino Acids 2008; 35(4):731-738.
7. Palka JA, Phang JM. Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptors. J Cell Biochem 1997;67(2):166-175.
8. Myara I, Wolfrom C, Charpentier C, Gautier M, Lemonnier A. Relationship between cell density and prolidase activity in human skin fibroblasts: effects of ascorbate and fructose. Biochimie 1984;66(6):445-449.
9. Altindag O, Celik H. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox Rep 2006;11(3): 131-135.
10. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997;82(2):291-295.
11. Cordero MD. Oxidative stress in fibromyalgia: pathophysiology and clinical implications. Reumatol Clin 2011;7(5):281-283.
12. Miyamae T, Seki M, Naga T, Uchino S, Asazuma H, Yoshida T, et al. Increased oxidative stress and coenzyme Q10 deficiency in juvenile fibromyalgia: amelioration of hypercholesterolemia and fatigue by ubiquinol-10 supplementation. Redox Rep 2013;18(1): 12-19.
13. Tsou PS, Talia NN, Pinney AJ, Kendzicky A, Piera-Velazquez S, Jimenez SA, et al. Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts. Arthritis Rheum 2012;64(6):1978-1989.
14. Yamamoto T. Autoimmune mechanisms of scleroderma and a role of oxidative stress. Self Nonself 2011;2(1):4-10.
15. Akkus S, Naziroglu M, Eris S, Yalman K, Yilmaz N, Yener M. Levels of lipid peroxidation, nitric oxide, and antioxidant vitamins in plasma of patients with fibromyalgia. Cell Biochem Funct 2009;27(4):181-185.
16. Cordero MD, de Miguel M, Moreno-Fernandez AM. Mitochondrial dysfunction in fibromyalgia and its implication in the pathogenesis of disease. Med Clin (Barc) 2011;136(6): 252-256.
17. Inanici F, Yunus MB. History of fibromyalgia: past to present. Curr Pain Headache Rep 2004;8(5):369-378.
18. Neyal M, Yimenicioglu F, Aydeniz A, Taskin A, Saglam S, Cekmen M, et al. Plasma nitrite levels, total antioxidant status, total oxidant status, and oxidative stress index in patients with tension-type headache and fibromyalgia. Clin Neurol Neurosurg 2013;115(6):736-740.
19. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18(5):728-733.
20. Armutlu K, Keser I, Korkmaz N, Akbiyik DI, Sumbuloglu V, Guney Z, et al. Psychometric study of Turkish version of Fatigue Impact Scale in multiple sclerosis patients. J Neurol Sci 2007;255(1-2):64-68.
21. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46(10):1121-1123.
22. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37(2):112-119.
23. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38(12):1103-1111.
24. Bolukbas C, Bolukbas FF, Horoz M, Aslan M, Celik H, Erel O. Increased oxidative stress associated with the severity of the liver disease in various forms of hepatitis B virus infection. BMC Infect Dis 2005;5:95.
25. Aslan M, Sabuncu T, Kocyigit A, Celik H, Selek S. Relationship between total oxidant status and severity of diabetic nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2007; 17(10):734-740.
26. Myara I, Charpentier C, Lemonnier A. Optimal conditions for prolidase assay by proline colorimetric determination: application to iminodipeptiduria. Clin Chim Acta 1982;125(2): 193-205.
27. Chinard FP. Photometric estimation of proline and ornithine. J Biol Chem 1952;199(1):91-95.
28. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of pheno-types by their response to salts. Am J Hum Genet 1983;35(2): 214-227.
29. Myara I, Myara A, Mangeot M, Fabre M, Charpentier C, Lemonnier A. Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease. Clin Chem 1984;30(2): 211-215.
30. Karna E, Surazynski A, Palka J. Collagen metabolism disturbances are accompanied by an increase in prolidase activity in lung carcinoma planoepitheliale. Int J Exp Pathol 2000;81(5): 341-347.
31. Wolanska M, Sobolewski K, Drozdzewicz M. Integrins and prolidase activity in uterine leiomyoma during tumor growth. Ginekol Pol 2001;72(3):121-126.
32. Wolczynski S, Surazynski A, Swiatecka J, Palka J. Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells. Gynecol Endocrinol 2001;15(3): 225-233.
33. Deberg M, Labasse A, Christgau S, Cloos P, Bang Henriksen D, Chapelle JP, et al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005;13(3): 258-265.
34. Duong HS, Zhang QZ, Le AD, Kelly AP, Kamdar R, Messadi DV. Elevated prolidase activity in keloids: correlation with type I collagen turnover. Br J Dermatol 2006;154:820-828.
35. Hilali N, Vural M, Camuzcuoglu H, Camuzcuoglu A, Aksoy N. Increased prolidase activity and oxidative stress in PCOS. Clin Endocrinol (Oxf) 2013;79(1):105-110.
36. Gencer M, Aksoy N, Dagli EC, Uzer E, Aksoy S, Selek S, et al. Prolidase activity dysregulation and its correlation with oxi-dative-antioxidative status in chronic obstructive pulmonary disease. J Clin Lab Anal 2011;25(1):8-13.
37. Fitzcharles MA, Ste-Marie PA, Pereira JX. Canadian Fibromyalgia Guidelines C. Fibromyalgia: evolving concepts over the past 2 decades. CMAJ 2013;17(185):E645-E651.
38. Cakmak A, Soker M, Koc A, Erel O. Paraoxonase and arylester-ase activity with oxidative status in children with thalassemia major. J Pediatr Hematol Oncol 2009;31(8):583-587.
39. Borba EF, Borges CT, Bonfa E. Lipoprotein profile in limited systemic sclerosis. Rheumatol Int 2005;25(5):379-383.
40. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21(4):473-480.
41. Malin R, Jarvinen O, Sisto T, Koivula T, Lehtimaki T. Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis. Atherosclerosis 2001;157(2):301-307.
42. Altindag O, Gur A, Calgan N, Soran N, Celik H, Selek S. Paraoxonase and arylesterase activities in fibromyalgia. Redox Rep 2007;12(3):134-138.
43. Cordero MD, Diaz-Parrado E, Carrion AM, Alfonsi S, Sanchez-Alcazar JA, Bullon P, et al. Is inflammation a mitochondrial dysfunction-dependent event in fibromyalgia? Antioxid Redox Signal 2013;18(7):800-807.
44. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxf) 2001;40(7):743-749.
45. Cordero MD, Alcocer-Gomez E, Cano-Garcia FJ, De Miguel M, Carrion AM, Navas P, et al. Clinical symptoms in fibromyal-gia are better associated to lipid peroxidation levels in blood mononuclear cells rather than in plasma. PLoS One 2011; 6(10):e26915.